Active tuberculosis is caused by Mycobacterium tuberculosis, an airborne pathogen transmitted via aerosolized droplet nuclei. It affects the lungs in 70–80% of cases but can involve virtually any organ system. [1-2] TB remains a leading infectious cause of death worldwide, with approximately one-third of cases going undiagnosed. [3]
1. History
- Duration of cough: Persistent cough ≥2–3 weeks is the cardinal screening symptom; productive, may be blood-tinged [4-5]
- Constitutional symptoms: Fever (often low-grade, afternoon/evening), drenching night sweats, unintentional weight loss, anorexia, fatigue [6-7]
- Hemoptysis: Ranges from blood-streaked sputum to massive hemoptysis (suggests cavitary disease)
- Chest pain: Pleuritic pain may indicate pleural involvement
- Timing/progression: Insidious onset over weeks to months; subacute trajectory distinguishes TB from typical bacterial pneumonia [4]
- Exposure history: Close contact with known or suspected TB case, duration and setting of exposure
- Travel/residence: Birth in or travel to high-prevalence countries (sub-Saharan Africa, Southeast Asia, South Asia, Eastern Europe) [5]
- Prior TB history: Previous LTBI diagnosis, prior TB treatment, prior positive TST/IGRA
- Immunosuppression: HIV status, TNF-α inhibitor use, organ transplant, corticosteroid use, diabetes, chronic renal failure [8-9]
- Congregate settings: Incarceration, homeless shelters, long-term care facilities [4]
- Important negatives: Absence of cough does not exclude TB, especially in HIV-positive patients; up to 10% of HIV-associated TB cases are subclinical [2]
2. Alarm Features
- Massive hemoptysis (>300 mL/24 hours) — risk of airway compromise and hemorrhagic shock
- Altered mental status, neck stiffness, focal neurological deficits — suspect TB meningitis, the most severe form of extrapulmonary TB [10-11]
- Acute respiratory distress — miliary TB can progress to ARDS with mortality rates of 47–58% in adults [12-13]
- Signs of disseminated/miliary disease: Diffuse miliary pattern on CXR, hepatosplenomegaly, pancytopenia, choroid tubercles on fundoscopy (pathognomonic) [12]
- Hemodynamic instability with pericardial effusion — TB pericarditis with tamponade physiology [14]
- Failure to improve on standard antibiotics for community-acquired pneumonia after 7 days in a high-risk patient [4]
- Severely immunocompromised patients (CD4 <200): Atypical presentations with lower lobe infiltrates, hilar adenopathy, or normal CXR; disseminated disease with mycobacteremia [2]
3. Medications
Standard Treatment (Drug-Susceptible TB) per ATS/CDC/IDSA guidelines: [15-16]
- Intensive phase (2 months): Isoniazid (INH) + Rifampin (RIF) + Pyrazinamide (PZA) + Ethambutol (EMB) — daily dosing preferred
- Continuation phase (4 months): INH + RIF daily (or thrice weekly under DOT)
- Pyridoxine (vitamin B6) 25–50 mg/day: Given with INH to all patients to prevent peripheral neuropathy [16]
- EMB can be discontinued once susceptibility to INH and RIF is confirmed [15]
Key dosing: [17-18]
- INH: 5 mg/kg/day (max 300 mg)
- RIF: 10 mg/kg/day (max 600 mg)
- PZA: 25–35 mg/kg/day (max 2,000 mg)
- EMB: 15–25 mg/kg/day
Newer 4-month regimen (alternative): Rifapentine + moxifloxacin + INH + PZA for 8 weeks, then rifapentine + moxifloxacin + INH for 9 weeks — shown non-inferior to standard 6-month regimen [19]
Critical drug interactions (rifampin is a potent CYP450 inducer): [5][20]
- Reduces levels of: warfarin, oral contraceptives, methadone, protease inhibitors, NNRTIs, dolutegravir (dose adjustment needed), corticosteroids, azole antifungals, many others
- Rifabutin is preferred over rifampin in patients on certain antiretroviral regimens [19]
Contraindicated/caution medications:
- Avoid monotherapy with any single anti-TB drug (promotes resistance)
- Fluoroquinolones: QTc prolongation risk, especially with bedaquiline or clofazimine [21-22]
The following table from an NEJM review summarizes TB drug dosing and key considerations:
4. Diet
- Nutritional optimization is critical — malnutrition is both a risk factor for TB and a consequence of active disease; undernutrition accounts for an estimated 26.9% of attributable risk [23]
- High-protein, calorie-dense diet to support recovery and weight regain
- Avoid alcohol: Increases hepatotoxicity risk with INH, RIF, and PZA [15][19]
- Avoid milk, antacids, and divalent cations within 2 hours of fluoroquinolone or EMB dosing (impairs absorption) [16]
- Administer medications with food to reduce GI side effects [16]
5. Review of Systems
- Pulmonary: Cough (productive/dry), hemoptysis, dyspnea, pleuritic chest pain
- Constitutional: Fever, night sweats, weight loss, fatigue, anorexia
- Neurological: Headache, confusion, neck stiffness, focal deficits (TB meningitis) [10]
- Musculoskeletal: Back pain (Pott disease/spinal TB), joint pain [24]
- GI: Abdominal pain, diarrhea, ascites (peritoneal TB)
- GU: Dysuria, hematuria, flank pain (renal TB — can present years after primary infection) [24]
- Lymphatic: Painless lymphadenopathy, especially cervical (scrofula)
- Dermatologic: Erythema nodosum (hypersensitivity reaction)
- Cardiac: Chest pain, dyspnea, orthopnea (pericardial TB) [14]
6. Collateral History and Family History
- Household contacts: Any known TB cases, duration and proximity of exposure; household contact infection is more likely with smear-positive index cases [25]
- Immigration history: Country of origin, time since arrival, TB prevalence in home country
- Occupational exposure: Healthcare workers, correctional facility staff, laboratory workers
- Social context: Homelessness, substance use, incarceration history, crowded living conditions
- Family history: Congenital immunodeficiencies (chronic granulomatous disease, common variable immunodeficiency) increase susceptibility [8]
- HIV status of household members: Impacts contact investigation urgency
7. Risk Factors
- HIV infection — strongest individual risk factor; 8–10% annual progression rate without ART [1][9]
- Close contact with active pulmonary TB case [26]
- Immigration from high-prevalence countries [5]
- Diabetes mellitus — 7.5% attributable risk [23]
- Immunosuppressive therapy: TNF-α inhibitors, corticosteroids, post-transplant immunosuppression [9][27]
- Chronic kidney disease/dialysis [8]
- Silicosis [8]
- Active smoking — 15.8% attributable risk [23]
- Alcohol misuse — 9.8% attributable risk [23]
- Malnutrition/low BMI — 26.9% attributable risk [23]
- Congregate settings: Prisons, homeless shelters, nursing homes [4]
- Extremes of age: Infants (<1 year) and elderly [11]
- Chronic lung disease/COPD/bronchiectasis — 1.44–3.14-fold increased risk [27]
- Prior untreated LTBI: Greatest risk of progression in first 2 years [9]
8. Differential Diagnosis
- Lung cancer/lymphoma: Especially with upper lobe mass, weight loss, hemoptysis — biopsy may be needed to distinguish
- Community-acquired pneumonia: Shorter duration, acute onset; consider TB if no improvement after 7 days of antibiotics in high-risk patients [4]
- Non-tuberculous mycobacterial (NTM) infection: Similar CXR findings; AFB smear cannot distinguish from TB (requires NAAT or culture) [1]
- Lung abscess/aspergilloma: Cavitary lesions; aspergilloma can colonize old TB cavities
- Sarcoidosis: Bilateral hilar lymphadenopathy, non-caseating granulomas; can mimic TB clinically and radiographically
- Fungal infections: Histoplasmosis, coccidioidomycosis, blastomycosis — geographic exposure history is key
- HIV-associated opportunistic infections: PCP, MAC, CMV — especially at low CD4 counts
- Melioidosis: In endemic areas (Southeast Asia, Northern Australia)
- Empyema: Pleural TB can mimic bacterial empyema
9. Past Medical History
- Prior TB disease or LTBI (treated or untreated)
- HIV/AIDS status and CD4 count, ART regimen
- Diabetes mellitus (increases risk and may alter presentation)
- Chronic liver disease (impacts drug selection and monitoring)
- Chronic kidney disease (dose adjustments for EMB, PZA)
- History of organ transplantation or immunosuppressive therapy
- Silicosis or other occupite lung disease
- Prior BCG vaccination (affects TST interpretation, not IGRA)
- Substance use history (alcohol, IV drugs)
- Pregnancy status (affects drug selection; PZA avoided in some guidelines)
10. Physical Exam
- Vital signs: Low-grade fever, tachycardia, tachypnea; may be afebrile
- General: Cachexia, wasting, diaphoresis
- Pulmonary: Crackles/rales (especially apical), bronchial breath sounds, amphoric breathing over cavities; exam may be surprisingly normal
- Lymph nodes: Cervical lymphadenopathy (scrofula) — matted, non-tender, may be fluctuant [11]
- Abdomen: Hepatosplenomegaly (miliary/disseminated TB), ascites (peritoneal TB)
- Neurological: Meningismus, cranial nerve palsies (especially CN VI), altered consciousness (TB meningitis) [10]
- Spine: Gibbus deformity (Pott disease), paraspinal tenderness [24]
- Fundoscopy: Choroid tubercles — pathognomonic for miliary TB [12]
- Cardiac: Pericardial friction rub, muffled heart sounds, Beck's triad (TB pericarditis) [14]
- Skin: Erythema nodosum, lupus vulgaris (rare)
11. Lab Studies
Diagnostic labs: [1][9][15]
- AFB smear microscopy: 3 sputum specimens collected 8–24 hours apart (at least one early morning); fluorescence microscopy preferred; sensitivity ~50–80% for smear-positive disease
- Mycobacterial culture (liquid + solid media): Gold standard; takes 2–8 weeks; perform drug susceptibility testing on all positive cultures
- Nucleic acid amplification test (NAAT): Xpert MTB/RIF or Xpert Ultra on initial specimen — results in <2 hours; also detects rifampin resistance [6][9]
- Drug susceptibility testing: First-line (INH, RIF, EMB, PZA) on all positive cultures; second-line if resistance detected
Baseline labs before treatment: [5][15]
- CBC with differential
- Hepatic panel (AST, ALT, bilirubin, alkaline phosphatase)
- BMP (creatinine, electrolytes)
- HIV testing (mandatory for all TB patients)
- Hepatitis B and C serologies
- Uric acid (baseline before PZA)
- Visual acuity and color vision testing (baseline before EMB)
- Pregnancy test in women of childbearing age
Monitoring during treatment: [5][15]
- Monthly sputum AFB smear and culture until 2 consecutive negatives
- LFTs: Monthly if risk factors for hepatotoxicity; otherwise symptom-directed
- DILI criteria: ALT ≥3× ULN with symptoms, or ≥5× ULN without symptoms → stop hepatotoxic drugs [15][19]
- Visual acuity monthly while on EMB
12. Imaging
First-line: Chest radiograph (PA and lateral): [4]
- Classic findings (immunocompetent): Upper lobe infiltrates, cavitation, fibrosis, volume loss
- Atypical findings (HIV/immunosuppressed): Lower lobe infiltrates, hilar/mediastinal lymphadenopathy, interstitial pattern, pleural effusion, or normal CXR [2][4]
- Miliary pattern: Diffuse 1–2 mm nodules throughout both lung fields [12]
CT chest: More sensitive than CXR for detecting cavitation, lymphadenopathy, tree-in-bud pattern, miliary nodules; useful when CXR is equivocal or for extrapulmonary disease evaluation
When imaging is unnecessary: A normal CXR in an immunocompetent patient with no symptoms effectively excludes active pulmonary TB [28]
Extrapulmonary imaging: [24]
- MRI brain/spine: TB meningitis (basal meningeal enhancement, hydrocephalus), spinal TB (vertebral destruction, paraspinal abscess)
- CT abdomen: Necrotic lymph nodes, hepatosplenic microabscesses, peritoneal thickening
- Ultrasound: Pericardial effusion, ascites, lymphadenopathy
13. Special Tests
- Xpert MTB/RIF Ultra: Rapid NAAT with high sensitivity (~88% pooled) and specificity (~99%); simultaneously detects rifampin resistance; results in <2 hours [6]
- TST/IGRA: Supports diagnosis but cannot distinguish LTBI from active disease; a negative result does not exclude active TB (especially in immunosuppressed) [1][5]
- Adenosine deaminase (ADA): Elevated in TB pleural effusion, peritoneal TB, TB meningitis — useful adjunctive test
- Urine lipoarabinomannan (LAM): Point-of-care test useful in HIV-positive patients with low CD4 counts
- Bronchoscopy with BAL: When sputum cannot be obtained or smears are negative; perform under airborne precautions [15]
- Sputum induction: With hypertonic saline when patient cannot spontaneously expectorate
- Biopsy: Lymph node, pleural, peritoneal, or other tissue — caseating granulomas with or without AFB
14. ECG
- Standard first-line regimen (RIPE): The standard 6-month regimen does not carry a sizable risk of QT prolongation [29]
- Fluoroquinolones (moxifloxacin > levofloxacin): QTc prolongation risk; serial ECG monitoring recommended, especially in older patients and those with cardiovascular risk factors [22]
- MDR-TB drugs: Bedaquiline and delamanid both cause modest QTc prolongation; peak effect at 5–8 weeks (delamanid) and 24 weeks (bedaquiline) [21]
- Baseline ECG recommended before starting fluoroquinolones, bedaquiline, or delamanid; repeat at weeks 2, 8, and 16 for bedaquiline-containing regimens [21]
- QTcF >500 ms or increase >60 ms from baseline: Hold offending agent, correct electrolytes (K⁺, Mg²⁺, Ca²⁺), evaluate concomitant QT-prolonging medications [30-31]
- TB pericarditis: Low-voltage QRS, electrical alternans (if large effusion), diffuse ST elevation [14]
15. Assessment
- Active pulmonary TB is a reportable disease — all suspected and confirmed cases must be reported to the local/state health department [1][5]
- Severity stratification:
- Uncomplicated pulmonary TB: Standard 6-month RIPE regimen
- Cavitary disease with positive 2-month culture: Extend continuation phase to 7 months (total 9 months) [15]
- Disseminated/miliary TB: High mortality (16–38%, higher with ARDS); requires ICU-level care if respiratory failure [12-13]
- TB meningitis: Requires intensified regimen with higher-dose INH and RIF, adjunctive corticosteroids [20]
- Atypical presentations: HIV-positive patients, elderly, children, and immunosuppressed patients frequently present without classic upper lobe cavitary disease [2][4]
- Complications: ARDS, massive hemoptysis, bronchopleural fistula, constrictive pericarditis, Addison disease, amyloidosis, bronchiectasis
16. Treatment Plan
Initial stabilization (ED):
- Airborne isolation immediately upon suspicion (negative-pressure room, N95 respirators for staff) [4]
- Collect 3 sputum specimens for AFB smear, culture, and NAAT before or promptly after starting treatment [9][15]
- Do not delay empiric treatment in seriously ill patients pending results [15]
Standard drug-susceptible regimen: [15-16]
- Intensive phase (8 weeks): INH + RIF + PZA + EMB daily
- Continuation phase (18 weeks): INH + RIF daily or thrice weekly
- Pyridoxine 25–50 mg/day with all INH-containing regimens [16]
- Directly observed therapy (DOT) is strongly recommended [15]
Special situations:
- HIV co-infection: Start ART within 2 weeks if CD4 <50; within 8 weeks for higher CD4 counts; use rifabutin if drug interactions preclude rifampin [19]
- TB meningitis: Extend treatment to 9–12 months; adjunctive dexamethasone [20]
- Drug-resistant TB: Consult infectious disease specialist; bedaquiline-based regimens (BPaL) for MDR-TB [7]
- Pregnancy: INH + RIF + EMB for 9 months (PZA avoided in U.S. guidelines due to limited safety data); pyridoxine essential
Hepatotoxicity management: [15][19][23]
17. Disposition
Admission criteria:
- Hemodynamic instability, respiratory failure, or ARDS
- Suspected miliary/disseminated TB or TB meningitis
- Massive hemoptysis
- Inability to tolerate oral medications
- Social factors precluding safe outpatient isolation (homelessness, congregate living)
- Need for airborne infection isolation when outpatient isolation is not feasible
Discharge criteria: [26]
- On effective multidrug regimen with clinical improvement
- Three consecutive AFB smear-negative sputum specimens collected 8–24 hours apart (at least one early morning)
- Adequate outpatient isolation plan in place
- Coordination with local TB control program for DOT
Observation indications:
- Awaiting sputum results in patients with moderate clinical suspicion
- Rapid molecular testing (Xpert MTB/RIF) can reduce isolation duration from days to hours [32]
Specialist consultation triggers:
- Infectious disease: All confirmed cases; mandatory for drug-resistant TB, HIV co-infection, extrapulmonary TB
- Pulmonology: Massive hemoptysis, need for bronchoscopy
- Neurosurgery: TB meningitis with hydrocephalus requiring shunt
- Cardiothoracic surgery: Constrictive pericarditis, bronchopleural fistula
- Public health department: All suspected and confirmed cases [4]
18. Follow Up / Return Precautions
Follow-up timing:
- Monthly clinical evaluation during treatment (symptoms, weight, medication adherence, adverse effects) [5]
- Monthly sputum cultures until conversion documented [15]
- LFTs monthly if risk factors; otherwise symptom-directed [15]
- Visual acuity testing monthly while on EMB [5]
- End-of-treatment evaluation; some experts recommend CXR at completion
Symptoms requiring immediate reassessment:
- Jaundice, dark urine, severe nausea/vomiting, RUQ pain (hepatotoxicity)
- Visual changes or loss of color discrimination (EMB toxicity)
- Worsening cough, hemoptysis, dyspnea, or fever after initial improvement
- Numbness/tingling in extremities (peripheral neuropathy)
- Rash, persistent fever, or signs of drug hypersensitivity
- Confusion, headache, neck stiffness (CNS involvement)
Patient counseling points:
- TB is curable with complete treatment; adherence to the full course is critical — 16–49% of patients do not complete therapy [18]
- Medications must be taken as prescribed under DOT; missed doses can lead to drug resistance and treatment failure
- Avoid alcohol throughout treatment
- Use reliable contraception (rifampin reduces efficacy of oral contraceptives)
- Respiratory hygiene: Cover cough, wear mask around others until deemed non-infectious
- Expected recovery: Clinical improvement typically within 2–4 weeks; full treatment course is 6–9 months
Expected recovery course: Fever and constitutional symptoms generally improve within 2 weeks of effective therapy. Infectiousness declines rapidly — after 14–21 days of treatment, infectiousness averages <1% of pretreatment levels. [26] Sputum culture conversion typically occurs by 2 months in drug-susceptible TB.
References
1. Tuberculosis. — John A. Jereb CDC Yellow Book. 2025.
2. Tuberculosis. — John A. Jereb CDC Yellow Book. 2025.
3. Tuberculosis. — John A. Jereb CDC Yellow Book. 2025.
4. Tuberculosis. — Zumla A, Raviglione M, Hafner R, von Reyn CF. The New England Journal of Medicine. 2013.
5. Tuberculosis. — Zumla A, Raviglione M, Hafner R, von Reyn CF. The New England Journal of Medicine. 2013.
6. Xpert MTB/RIF and Xpert Ultra Assays for Screening for Pulmonary Tuberculosis and Rifampicin Resistance in Adults, Irrespective of Signs or Symptoms. — Shapiro AE, Ross JM, Yao M, et al. The Cochrane Database of Systematic Reviews. 2021.
7. Xpert MTB/RIF and Xpert Ultra Assays for Screening for Pulmonary Tuberculosis and Rifampicin Resistance in Adults, Irrespective of Signs or Symptoms. — Shapiro AE, Ross JM, Yao M, et al. The Cochrane Database of Systematic Reviews. 2021.
8. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United States. — American Journal of Respiratory and Critical Care Medicine. 2005.
9. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United States. — American Journal of Respiratory and Critical Care Medicine. 2005.
10. Tuberculosis: Common Questions and Answers. — Hartman-Adams H, Gerbo RM, George S. American Family Physician. 2022.
11. Tuberculosis: Common Questions and Answers. — Hartman-Adams H, Gerbo RM, George S. American Family Physician. 2022.
12. Xpert MTB/RIF Ultra Assay for Pulmonary Tuberculosis and Rifampicin Resistance in Adults and Adolescents. — Horne DJ, Zifodya JS, Shapiro AE, et al. The Cochrane Database of Systematic Reviews. 2025.
13. Xpert MTB/RIF Ultra Assay for Pulmonary Tuberculosis and Rifampicin Resistance in Adults and Adolescents. — Horne DJ, Zifodya JS, Shapiro AE, et al. The Cochrane Database of Systematic Reviews. 2025.
14. Xpert MTB/XDR for Detection of Pulmonary Tuberculosis and Resistance to Isoniazid, Fluoroquinolones, Ethionamide, and Amikacin. — Pillay S, Steingart KR, Davies GR, et al. The Cochrane Database of Systematic Reviews. 2022.
15. Xpert MTB/XDR for Detection of Pulmonary Tuberculosis and Resistance to Isoniazid, Fluoroquinolones, Ethionamide, and Amikacin. — Pillay S, Steingart KR, Davies GR, et al. The Cochrane Database of Systematic Reviews. 2022.
16. Tuberculosis Comorbidity With Communicable and Non-Communicable Diseases: Integrating Health Services and Control Efforts. — Marais BJ, Lönnroth K, Lawn SD, et al. The Lancet. Infectious Diseases. 2013.
17. Tuberculosis Comorbidity With Communicable and Non-Communicable Diseases: Integrating Health Services and Control Efforts. — Marais BJ, Lönnroth K, Lawn SD, et al. The Lancet. Infectious Diseases. 2013.
18. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. — Lewinsohn DM, Leonard MK, LoBue PA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017.
19. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. — Lewinsohn DM, Leonard MK, LoBue PA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017.
20. Low-Complexity Automated Nucleic Acid Amplification Tests for Extrapulmonary Tuberculosis and Rifampicin Resistance in Adults and Adolescents. — Kohli M, Inbaraj LR, Salomon A, et al. The Cochrane Database of Systematic Reviews. 2025.
21. Low-Complexity Automated Nucleic Acid Amplification Tests for Extrapulmonary Tuberculosis and Rifampicin Resistance in Adults and Adolescents. — Kohli M, Inbaraj LR, Salomon A, et al. The Cochrane Database of Systematic Reviews. 2025.
22. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
23. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
24. Miliary Tuberculosis. — Sharma SK, Mohan A. Microbiology Spectrum. 2017.
25. Miliary Tuberculosis. — Sharma SK, Mohan A. Microbiology Spectrum. 2017.
26. Tuberculosis as a Primary Cause of Respiratory Failure Requiring Mechanical Ventilation. — Penner C, Roberts D, Kunimoto D, Manfreda J, Long R. American Journal of Respiratory and Critical Care Medicine. 1995.
27. Tuberculosis as a Primary Cause of Respiratory Failure Requiring Mechanical Ventilation. — Penner C, Roberts D, Kunimoto D, Manfreda J, Long R. American Journal of Respiratory and Critical Care Medicine. 1995.
28. Infections and Cardiovascular Disease: JACC Focus Seminar 1/4. — Farina JM, Liblik K, Iomini P, et al. Journal of the American College of Cardiology. 2023.
29. Infections and Cardiovascular Disease: JACC Focus Seminar 1/4. — Farina JM, Liblik K, Iomini P, et al. Journal of the American College of Cardiology. 2023.
30. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. — Nahid P, Dorman SE, Alipanah N, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2016.
31. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. — Nahid P, Dorman SE, Alipanah N, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2016.
32. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. — Saukkonen JJ, Duarte R, Munsiff SS, et al. American Journal of Respiratory and Critical Care Medicine. 2025.
33. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. — Saukkonen JJ, Duarte R, Munsiff SS, et al. American Journal of Respiratory and Critical Care Medicine. 2025.
34. FDA Drug Label. — Updated date: 2024-11-07. Food and Drug Administration.
35. FDA Drug Label. — Updated date: 2024-11-07. Food and Drug Administration.
36. Treatment of Tuberculosis. — Horsburgh CR, Barry CE, Lange C. The New England Journal of Medicine. 2015.
37. Treatment of Tuberculosis. — Horsburgh CR, Barry CE, Lange C. The New England Journal of Medicine. 2015.
38. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
39. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
40. A Clinical Practice Guideline for Tuberculous Meningitis. — Donovan J, Cresswell FV, Tucker EW, et al. The Lancet. Infectious Diseases. 2026.
41. A Clinical Practice Guideline for Tuberculous Meningitis. — Donovan J, Cresswell FV, Tucker EW, et al. The Lancet. Infectious Diseases. 2026.
42. QT Effects of Bedaquiline, Delamanid, or Both in Patients With Rifampicin-Resistant Tuberculosis: A Phase 2, Open-Label, Randomised, Controlled Trial. — Dooley KE, Rosenkranz SL, Conradie F, et al. The Lancet. Infectious Diseases. 2021.
43. QT Effects of Bedaquiline, Delamanid, or Both in Patients With Rifampicin-Resistant Tuberculosis: A Phase 2, Open-Label, Randomised, Controlled Trial. — Dooley KE, Rosenkranz SL, Conradie F, et al. The Lancet. Infectious Diseases. 2021.
44. Serial Electrocardiogram Recordings Revealed a High Prevalence of QT Interval Prolongation in Patients With Tuberculosis Receiving Fluoroquinolones. — Ju KS, Lee RG, Lin HC, et al. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 2023.
45. Serial Electrocardiogram Recordings Revealed a High Prevalence of QT Interval Prolongation in Patients With Tuberculosis Receiving Fluoroquinolones. — Ju KS, Lee RG, Lin HC, et al. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 2023.
46. Tuberculosis. — Dheda K, Barry CE, Maartens G. Lancet. 2016.
47. Tuberculosis. — Dheda K, Barry CE, Maartens G. Lancet. 2016.
48. Extrapulmonary Tuberculosis: Pathophysiology and Imaging Findings. — Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2019.
49. Extrapulmonary Tuberculosis: Pathophysiology and Imaging Findings. — Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2019.
50. Assessing Infectiousness and the Impact of Effective Treatment to Guide Isolation Recommendations for People With Pulmonary Tuberculosis. — Nathavitharana RR, Pearl A, Biewer A, et al. The Journal of Infectious Diseases. 2025.
51. Assessing Infectiousness and the Impact of Effective Treatment to Guide Isolation Recommendations for People With Pulmonary Tuberculosis. — Nathavitharana RR, Pearl A, Biewer A, et al. The Journal of Infectious Diseases. 2025.
52. NTCA Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings. — Shah M, Dansky Z, Nathavitharana R, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
53. NTCA Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings. — Shah M, Dansky Z, Nathavitharana R, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
54. Host Genetic Factors and Clinical Comorbidities Associated With Tuberculosis Risk. — Lin SP, Chen IC, Lin CH, et al. Hla. 2025.
55. Host Genetic Factors and Clinical Comorbidities Associated With Tuberculosis Risk. — Lin SP, Chen IC, Lin CH, et al. Hla. 2025.
56. Tuberculosis: A Focused Review for the Emergency Medicine Clinician. — Long B, Liang SY, Koyfman A, Gottlieb M. The American Journal of Emergency Medicine. 2020.
57. Tuberculosis: A Focused Review for the Emergency Medicine Clinician. — Long B, Liang SY, Koyfman A, Gottlieb M. The American Journal of Emergency Medicine. 2020.
58. Effects on the QT Interval of a Gatifloxacin-Containing Regimen Versus Standard Treatment of Pulmonary Tuberculosis. — Olliaro PL, Merle C, Mthiyane T, et al. Antimicrobial Agents and Chemotherapy. 2017.
59. Effects on the QT Interval of a Gatifloxacin-Containing Regimen Versus Standard Treatment of Pulmonary Tuberculosis. — Olliaro PL, Merle C, Mthiyane T, et al. Antimicrobial Agents and Chemotherapy. 2017.
60. QTc and Anti-Tuberculosis Drugs: A Perfect Storm or a Tempest in a Teacup? Review of Evidence and a Risk Assessment. — Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, et al. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union Against Tuberculosis and Lung Disease. 2018.
61. QTc and Anti-Tuberculosis Drugs: A Perfect Storm or a Tempest in a Teacup? Review of Evidence and a Risk Assessment. — Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, et al. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union Against Tuberculosis and Lung Disease. 2018.
62. QTc Prolongation and Treatment of Multidrug-Resistant Tuberculosis. — Harausz E, Cox H, Rich M, et al. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union Against Tuberculosis and Lung Disease. 2015.
63. QTc Prolongation and Treatment of Multidrug-Resistant Tuberculosis. — Harausz E, Cox H, Rich M, et al. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union Against Tuberculosis and Lung Disease. 2015.
64. Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital. — Chaisson LH, Duong D, Cattamanchi A, et al. JAMA Internal Medicine. 2018.
65. Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital. — Chaisson LH, Duong D, Cattamanchi A, et al. JAMA Internal Medicine. 2018.